HOME >> BIOLOGY >> NEWS
Molecular mechanism of feather formation found

MADISON - Feathers are the essence of birds. Without them, birds could not fly or attract mates. But how exactly do feathers form molecularly? Experimentally testing one current hypothesis, developmental biologists at University of Wisconsin Medical School believe they now have the answer.

In a previous study, UW anatomy professor John F. Fallon and his team showed that Sonic hedgehog (Shh) and bone morphogenetic protein 2 (Bmp2) must be expressed in order to produce barb ridges, which are among the first structures to form in the tufted branches of the simple downy chick feather. The two proteins, which tend to play off each other in organ development, also are involved in the embryonic development of limbs, lungs, teeth and the gut.

In the current study, appearing in the Aug. 16 Proceedings of the National Academy of Sciences (PNAS Online, Aug. 8), Fallon's team and collaborators showed that during the development of barbs-filamentous structures that form the feather-the function of these two proteins interact. SHH up-regulates its own expression and that of Bmp2, and Bmp2 then signals the down-regulation of Shh expression. This dynamic signaling interaction fits a longstanding mathematical model known as an activator-inhibitor mechanism, says lead author Matthew P. Harris, Fallon's graduate student now doing a postdoctoral fellowship with Nobel Laureate Christiane Nusslein-Volhard at Max Plank Institute in Tubingen, Germany.

"In this model, the inhibitor down-regulates activator function, the activator up-regulates its own expression and the activator also increases the activity of the inhibitor," Harris says. "The model is a simple way of explaining how feather patterning is achieved."

Theoretical biologist Hans Meinhardt, also at the Max Plank Institute and a collaborator on the PNAS paper, posited the role of the activator-inhibitor model in developmental patterning in animals years ago. Through the combined efforts of Meinhar
'"/>

Contact: John Fallon
jffallon@facstaff.wisc.edu
608-262-3775
University of Wisconsin-Madison
10-Aug-2005


Page: 1 2 3

Related biology news :

1. Molecular detectors may refine cancer treatment
2. Story ideas from Molecular & Cellular Proteomics
3. 2007 Image of the Year: Molecular imaging relates human brain chemistry to aggressive behavior
4. Molecular motors may speed nutrient processing
5. Molecular rendezvous caught on camera
6. Molecular tools make the cut
7. Genomatix and Molecular Connections form strategic partnership
8. Molecular motors and brakes work together in cells
9. Molecular link between inflammation and cancer discovered
10. Molecular on/off switch controls immune defenses against viruses
11. Molecular marker on stem cells aids research, perhaps therapies

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Molecular mechanism feather formation found

(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... New York College, and one of the most prolific ... signals that are transmitted from Smartphones to third party ... Smartphones and has one of the earliest known patents ... its usage in the military, child care, elder care ...
(Date:11/18/2014)... , Nov. 18, 2014  The Secure Identity ... Association today jointly announce the formation of The ... of its Identity and Biometric Entry and ... Framework received official support from BORDERPOL, the international ... improve and provide expertise regarding border security, traveler ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... ROCKVILLE, Md. , Dec. 17, 2014 ... biopharmaceutical company dedicated to the acquisition, development and commercialization ... needs for the global market with a primary commercial ... that it has been granted a Type C meeting ... that the meeting will be held in February 2015.  ...
(Date:12/17/2014)... 17, 2014   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, announced today its presentation at ... San Francisco, CA. ... Officer, will present on Monday, January 12, 2015, at ... be webcast live and may be accessed from the ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , Dec. ... BCLI ), a leading developer of adult stem ... subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a grant ... Office of the Chief Scientist (OCS).  This is ... of grant support from the Office of the Chief ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
Cached News: